Arbutus Biopharma Corpora... (ABUS)
3.29
-0.05 (-1.50%)
At close: Apr 25, 2025, 3:59 PM
3.35
1.82%
After-hours: Apr 25, 2025, 05:55 PM EDT
-1.50% (1D)
| Bid | 3.24 |
| Market Cap | 629.97M |
| Revenue (ttm) | 6.17M |
| Net Income (ttm) | -69.92M |
| EPS (ttm) | -0.38 |
| PE Ratio (ttm) | -8.66 |
| Forward PE | -32.45 |
| Analyst | Buy |
| Ask | 3.5 |
| Volume | 329,485 |
| Avg. Volume (20D) | 1,014,333 |
| Open | 3.31 |
| Previous Close | 3.34 |
| Day's Range | 3.25 - 3.32 |
| 52-Week Range | 2.63 - 4.72 |
| Beta | 1.45 |
About ABUS
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel ...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 26, 2007
Employees 44
Stock Exchange NASDAQ
Ticker Symbol ABUS
Website https://www.arbutusbio.com
Analyst Forecast
According to 4 analyst ratings, the average rating for ABUS stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 51.98% from the latest price.
Stock ForecastsNext Earnings Release
Arbutus Biopharma Corporation is scheduled to release its earnings on May 9, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 weeks ago
+7.03%
Arbutus Biopharma shares are trading higher on pos...
Unlock content with
Pro Subscription
5 months ago
+0.28%
Barinthus Biotherapeutics shares are trading lower. The company announced data from the ongoing Phase 2b HBV003 clinical trial.
